Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”

Babak Sayad, Fatemeh Norooznezhad, and Alireza Farokhi

1Liver Diseases Research Center, Kermanshah University of Medical Sciences, Iran

Dear Editor,

We are greatly fascinated by the article entitled “The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3” (1). It is a great honor that Sovodak (a fixed-dose combination of sofosbuvir 400 mg and daclatasvir 60 mg in a single pill), formulated in Iran, has shown such great effectiveness in the treatment of patients with chronic HCV infection and cirrhosis. The effort to achieve sustained virologic response (SVR) in these patients has been reported to be 92%, which is higher than the rates reported in similar studies.

The authors have suggested Sovodak for its ease of use as a single pill per day, its effectiveness as a panenotypic drug, and its use as the first choice of treatment for all HCV patients. They have also mentioned the lowest level of drug interactions between this combination and antiretroviral drugs, which makes it a good choice for HIV/HCV-coinfected patients (1).

Although the fixed-dose combination of sofosbuvir 400 mg and daclatasvir 60 mg can be used in most patients with chronic HCV infection of different genotypes (2, 3), it is crucial to adjust daclatasvir dose in patients with HIV coinfection, receiving antiretroviral drugs (4, 5). In fact, treatment of HIV/HCV-coinfected patients is of great intricacy (6), as they are more exposed to liver-related morbidity and mortality, as well as nonhepatic organ dysfunction in comparison to HCV-monoinfected patients (2).

On the other hand, HCV drug interactions with antiretroviral drugs make the treatment process even more complicated. Among Direct Acting Antiviral (DAA)-based treatment regimens for chronic HCV infection, the combination of daclatasvir and sofosbuvir has shown manageable interactions with anti-HIV drugs (7). Given the fact that daclatasvir is a substrate of CYP3A4 and that regimens containing etravirine and efavirenz decrease daclatasvir exposure through CYP3A4 induction, it seems necessary to increase the dose of daclatasvir to 90 mg daily in order to minimize the drug interactions (2, 3, 8).

Moreover, concomitant prescription of daclatasvir with antiretroviral regimens, which contain atazanavir/ritonavir and inhibit CYP3A4, would cause a 2.1-fold increase in the area under the curve (AUC) of daclatasvir (8). Likewise, a combination of atazanavir and cobicistat exhibits the same interactions with daclatasvir. Therefore, the dose of daclatasvir should be decreased to 30 mg daily when prescribed along with these antiretroviral drugs (2, 3, 8, 9).

Since efavirenz-containing treatment regimens are frequently prescribed for HIV-infected patients in Iran and regimens containing atazanavir and ritonavir are considered as the second line of treatment (10), simultaneous treatment of HCV infection with a fixed dose of daclatasvir in Sovodak is not recommended. Therefore, in case of using sofosbuvir plus daclatasvir in HIV/HCV-coinfected patients, it is of great necessity to use these medications separately so that daclatasvir dosage can be adjusted when needed. Fortunately, sofosbuvir 400 mg and daclatasvir 30 and 60 mg have been generically formulated in Iran, which facilitates the prescription of daclatasvir at doses of 30 to 90 mg for this patient population.

Acknowledgments

The authors are immensely grateful to Dr. Hengame Namdari Tabar and Dr. Katayoun Taeri for their kind help.

References


